29 Cost and Utility of Sentinel Lymph Node Biopsy in Patients Undergoing Breast Conservation Surgery for DCIS
34 12-Year Review of Surgical Outcomes in Implant-Based Reconstructions With Modification and Optimization of Mastectomy Flap Geometry and Soft Tissue Quality: a Retrospective Review of 900 Implant-Based Breast Reconstructions
10 Wire Localization vs Radar Reflector Localization: A Comparison
23 Trends in Screening and Diagnostic Mammogram Reimbursement From 2002 to 2022
38 Comparing Risk Stratification and Radiotherapy Benefit for Patients With DCIS Using a 7-Gene Biosignature as Compared to a Clinicopathologic Nomogram
39 7-Gene Predictive Biosignature Improves Risk Stratification for Breast Ductal Carcinoma In Situ Patients Compared to Clinicopathologic Criteria, Identifying a Low-Risk Group Not Clinically Benefiting from Adjuvant Radiotherapy
40 Characterization of Recurrence Risk After Lumpectomy and Radiotherapy in HER2-Positive Ductal Carcinoma in Situ of the Breast Using a 7-Gene Predictive Biosignature: Implications for the NSABP-B43 Trial Results
41 Changes in Treatment Recommendation for Patients With Ductal Carcinoma In Situ Using a 7-Gene Predictive Biosignature: Analysis of the PREDICT Study
43 Factors Affecting Survival in Solitary Bone-Only De Novo Stage IV Metastatic Breast Cancer
49 Financial Toxicity Among Patients With Breast Cancer During the COVID-19 Pandemic
51 The Race, Staging, and Clinical Correlations With Genetic Mutations Diagnosed in Breast Cancer Patients of Multiethnicity Background
54 Quality of Life With Ribociclib Plus Aromatase Inhibitor vs Abemaciclib Plus Aromatase Inhibitor as First-line Treatment of HR+/HER2− Advanced Breast Cancer, Assessed via Matching- Adjusted Indirect Comparison (MAIC)
